Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Solid Q3 and YTD performance
Group1
USD million
Q3
Change vs. PY
2022
9M
2022
Change vs. PY
% USD
% cc
% USD
% cc
Net Sales
12,543
-4
37,855
-1
Core Operating income
4,282
-4
5
12,635
-1
6
Operating income
2,168
-33
-23
7,248
-21
-13
Net Income
1,575
-43
-33
5,489
-29
-20
Growth ex. prior year Roche income
-38
-27
-21
-12
Core EPS (USD)
1.58
-8
1
4.60
-6
Growth ex. prior year Roche income
1
10
3
11
EPS (USD)
0.73
-41
-31
2.50
-27
-19
Growth ex. prior year Roche income
Free Cash Flow
-35
-25
-20
-10
4,169
-6
8,393
-18
Growth ex. prior year Roche dividend
-6
-14
1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 49 of the Condensed Financial Report. A table showing the Q3 2022 and 9M 2022 key
figures excluding Roche can be found on page 9 and a reconciliation of 2021 IFRS results and non-IFRS measures core results to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 57 of the Condensed
Interim Financial Report.
21 Investor Relations | Q3 2022 Results
ā NOVARTIS | Reimagining MedicineView entire presentation